J Crohns Colitis. 2021 Sep 25;15(9):1431-1442. doi: 10.1093/ecco-jcc/jjab050.

Bram Verstockt ^1 2, Nurulamin M Noor ^3 4, Urko M Marigorta ^5 6, Polychronis Pavlidis ^7 8, Parakkal Deepak ⁹, Ryan C Ungaro ¹⁰, Scientific Workshop Steering Committee

Author information

Collaborators

• Scientific Workshop Steering Committee: 

Claudio Fiocchi, Joana Torres, Michael Scharl

Affiliations

• ¹University Hospitals Leuven Department of Gastroenterology and Hepatology, KU Leuven, Leuven, Belgium.
• ²KU Leuven Department of Chronic Diseases and Metabolism, Translational Research Center for Gastrointestinal Disorders [TARGID], Leuven, Belgium.
• ³Department of Gastroenterology, Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, Cambridge, UK.
• ⁴Medical Research Council Clinical Trials Unit, University College London, London, UK.
• ⁵Integrative Genomics Lab, Center for Cooperative Research in Biosciences [CIC bioGUNE], Basque Research and Technology Alliance [BRTA], Derio, Spain.
• ⁶IKERBASQUE, Basque Foundation for Science, Bilbao, Spain.
• ⁷Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
• ⁸School of Immunology and Microbial Sciences, King's College London, London, UK.
• ⁹Inflammatory Bowel Diseases Center, Washington University in Saint Louis School of Medicine, St Louis, MO, USA.
• ¹⁰Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Abstract

Inflammatory bowel diseases [IBD] are a heterogeneous spectrum with two extreme phenotypes, Crohn's disease [CD] and ulcerative colitis [UC], which both represent numerous phenotypical variations. Hence, we should no longer approach all IBD patients similarly, but rather aim to rethink clinical classifications and modify treatment algorithms to usher in a new era of precision medicine in IBD. This scientific ECCO workshop aims to provide a state-of-the-art overview on prognostic and predictive markers, shed light on key questions in biomarker development, propose best practices in IBD biomarker development [including trial design], and discuss the potential for multi-omic data integration to help drive further advances to make precision medicine a reality in IBD.